Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy

Abstract

For targeted gastric carcinoma therapy, hyaluronic acid (HA)-modified layer-by-layer nanoparticles (NPs) are applied for improving anticancer treatment efficacy and reducing toxicity and side effects. The aim of this study was to develop HA-modified NPs for the co-loading of irinotecan (IRN) and 5-fluorouracil (5-FU). A novel polymer–chitosan (CH)–HA hybrid formulation (HA–CH–IRN/5-FU NPs) consisting of poly(d,l-lactide-co-glycolide) (PLGA) and IRN as the core, CH and 5-FU as a shell on the core and HA as the outmost layer was prepared. Its morphology, average size, zeta potential and drug encapsulation ability were evaluated. Human gastric carcinoma cells (MGC803 cells) and cancer-bearing mice were used for the testing of in vitro cytotoxicity and in vivo antitumor efficiency of NPs. HA–CH–IRN/5-FU NPs displayed enhanced antitumor activity in vitro and in vivo than non-modified NPs, single drug-loaded NPs and drugs solutions. The results demonstrate that HA–CH–IRN/5-FU NPs can achieve impressive antitumor activity and the novel targeted drug delivery system offers a promising strategy for the treatment of gastric cancer.

<p>Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles</p>

“…combination with cancer chemotherapy, and combination index (CI) was introduced by Chou and Talalay for quantification of synergistic or antagonistic effect. 44 FA-CBP /PTX-LPNs, CBP/PTX-LPNs, and free CBP/PTX showed CI 50 value <1, showing synergy effects ( Figure 5B).…”

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer

“…In this report, we describe the packaging of cisplatin, AZD2281, or BMN 673 monotherapies and cisplatin in combination with AZD2281 or BMN 673 in an LbL NP drug delivery platform for administration to orthotopic OVCAR8 HGSOC‐xenograft tumor‐bearing mice. This nano‐delivery platform employs liposomes modified with polyelectrolyte nano‐layers to provide improved biodistribution and a terminal functionality that enhances NP trafficking for drug delivery and colocalization into tumors . The liposomal NPs are layered by electrostatic deposition of a polycation, PLL, to provide structural stability and pH‐responsiveness in the tumor microenvironment, whereas the terminal polyanion layer of the NPs, HA, is critical for selective CD44 targeting of HGSOC tumor cells .…”

“…This nano-delivery platform employs liposomes modified with polyelectrolyte nano-layers to provide improved biodistribution and a terminal functionality that enhances NP trafficking for drug delivery and colocalization into tumors. 36,37,66,67 The liposomal NPs are layered by electrostatic deposition of a polycation, PLL, to provide structural stability and pH-responsiveness in the tumor microenvironment, whereas the terminal polyanion layer of the NPs, HA, is critical for selective CD44 targeting of HGSOC tumor cells. 68 The extravasation of LbL NPs from the blood circulation into the tumor microenvironment nucleic acids, such as siRNA or microRNA, that can modulate specific genetic pathways in tumors to elicit strong cytotoxic and immunomodulatory responses.…”

Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-&epsilon;-poly(caprolactone) nanocarriers

“…The DEE of 5-FU in NCs was quantified by high-performance liquid chromatography (LC-20A; Shimadzu, Tokyo, Japan) using 250×4.6 mm C18 column. 27 The mobile phase (0.05 M of KH 2 PO 4 contained 0.1% of triethylamine) has a flow rate of 0.6 mL/min, and ultraviolet detection was set at 266 nm. The DEE (%) was calculated according to the equation: (weight of 5-FU in NCs/weight of total 5-FU fed)×100.…”